Ticker: ABOS

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) - Quick read What's happening inside: Management is ramping clinical activity for sabirnetug (Phase 2 ALTITUDE-AD enrollment completed March 2025), increasing manufacturing and CRO spend to support the trial and a subcutaneous formulation program. The c...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has recently released its quarterly report for the period ended March 31, 2025. Here are the key highlights and insights derived from the financial statements and operational updates. Positive Aspects: Clinical Progress: The company has advanced its im...